New York, Feb 1, 2026, 10:50 EST — Market closed
- AbbVie shares closed Friday at $223.01, gaining roughly 1.2%.
- Focus now turns to this week’s earnings and the outlook for 2026.
- Macro noise remains elevated, pushing investors toward defensives.
AbbVie shares closed Friday at $223.01, rising $2.56, or roughly 1.2%. The week ahead could reshape forecasts for the drugmaker’s upcoming year. U.S. markets are closed Sunday, reopening Monday.
Friday’s action is crucial as investors await fresh data and, more importantly, updated guidance. For AbbVie, the key question remains: can its newer immunology drugs make up for the decline in legacy products, and will the aesthetics division hold steady?
In January, the company reported $1.3 billion in acquired in-process research and development (IPR&D) and milestone expenses for Q4 — a typical charge tied to acquisitions. It also noted that the quarter’s results “have not been finalized.” AbbVie issued full-year adjusted earnings guidance of $9.90 to $9.94, with quarterly guidance between $2.61 and $2.65. (SEC)
Friday’s gains stood out as the wider market dealt with fresh unease over interest rate trajectories and Washington politics. “Markets are calibrating to Trump’s pick of Kevin Warsh … and the outlook for monetary policy,” Michael Hans, chief investment officer at Citizens Wealth, said after Donald Trump tapped Warsh to head the Federal Reserve when Jerome Powell’s term expires. (Reuters)
AbbVie outpaced its big pharma peers, posting gains while Johnson & Johnson held steady and Amgen slipped. Pfizer climbed over 1%. Trading volume for AbbVie exceeded its 50-day average, though the stock still sits roughly 9% below its 52-week peak. (MarketWatch)
The schedule is packed. AbbVie is set to report on Wednesday, Feb. 4, with Kiplinger’s earnings preview pegging the estimate near $2.65 per share. (Kiplinger)
Traders are set to zero in on two key points: sales trends for Skyrizi and Rinvoq, plus any commentary on the Botox-driven aesthetics segment. With the stock viewed as a “safe” bet, management’s tone on guidance could overshadow the actual earnings report.
The tape could still shift before the week wraps. Investors are eyeing the U.S. January jobs report, with markets viewing major macro data as a direct signal on rates and risk appetite. (Investopedia)
But the situation works both ways. A cautious 2026 forecast, a slip in the main immunology brands, or an unexpected charge could drag AbbVie back down after its strong finish to the week.
The next major trigger is Wednesday’s earnings report, set for release before the market opens. The company also plans a webcasted conference call at 8 a.m. Central, it said. (Abbvie)
